How does the efficacy of COMP360 psilocybin treatment in reducing symptoms of bipolar II, as indicated by the -24.0 point change in MADRS scores, compare to traditional pharmacological treatments?

CYB003 showed a rapid reduction in depression symptoms after a single dose. Can you elaborate on the significance of this rapid onset of action compared to conventional antidepressants? How convinced are you about the results?

Both COMP360 and CYB003 have shown favorable safety profiles. How do these safety profiles compare to existing treatments for bipolar II or major depressive disorder?

Given the significant improvement in bipolar II symptoms with COMP360, what are the potential long-term implications for patients, especially in terms of maintaining remission and preventing relapses?

CYB003 demonstrated an unprecedented effect size (Cohen’s d > 2). Could you discuss the clinical relevance of this finding in the context of treating major depressive disorder?

• Based on the success of COMP360 in bipolar II and CYB003 in MDD, what other mental health conditions might benefit from psychedelic-based treatments?
• What are the primary challenges in integrating treatments like COMP360 and CYB003 into mainstream psychiatric practice?

Following the results from Phase 2 studies, what specific aspects do you think require further investigation in Phase 3 trials?

Can you give perspective on the opportunity of COMP360 to treat patients for TRD compared to existing treatments and other treatments in the pipeline.  Is its delivery method ((bout 8 hours in treatment center) a hurdle in patient acceptance?